Patel, K., Kilfoil, G., Wyles, D. L., Naggie, S., Lawitz, E., Bradley, S., … Suhy, D. (2016). 258. Phase I/IIa Study of TT-034, a DNA-Directed RNA Interference (ddRNAi) Agent Delivered as a Single Administration for the Treatment of Subjects with Chronic Hepatitis C Virus (HCV). In Molecular Therapy (Vol. 24, pp. S102–S102). Elsevier BV. https://doi.org/10.1016/s1525-0016(16)33067-2

Patel, Keyur, Georgina Kilfoil, David L. Wyles, Susanna Naggie, Eric Lawitz, Stephen Bradley, Per Lindell, and David Suhy. “258. Phase I/IIa Study of TT-034, a DNA-Directed RNA Interference (ddRNAi) Agent Delivered as a Single Administration for the Treatment of Subjects with Chronic Hepatitis C Virus (HCV).” In Molecular Therapy, 24:S102–S102. Elsevier BV, 2016. https://doi.org/10.1016/s1525-0016(16)33067-2.

Patel K, Kilfoil G, Wyles DL, Naggie S, Lawitz E, Bradley S, et al. 258. Phase I/IIa Study of TT-034, a DNA-Directed RNA Interference (ddRNAi) Agent Delivered as a Single Administration for the Treatment of Subjects with Chronic Hepatitis C Virus (HCV). In: Molecular Therapy. Elsevier BV; 2016. p. S102–S102.

Patel, Keyur, et al. “258. Phase I/IIa Study of TT-034, a DNA-Directed RNA Interference (ddRNAi) Agent Delivered as a Single Administration for the Treatment of Subjects with Chronic Hepatitis C Virus (HCV).” Molecular Therapy, vol. 24, Elsevier BV, 2016, pp. S102–S102. Crossref, doi:10.1016/s1525-0016(16)33067-2.

Patel K, Kilfoil G, Wyles DL, Naggie S, Lawitz E, Bradley S, Lindell P, Suhy D. 258. Phase I/IIa Study of TT-034, a DNA-Directed RNA Interference (ddRNAi) Agent Delivered as a Single Administration for the Treatment of Subjects with Chronic Hepatitis C Virus (HCV). Molecular Therapy. Elsevier BV; 2016. p. S102–S102.